Who are BAY86-5046_Interferon-beta-1b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Interferon Beta 1, Ganovo+ritonavir+/-Interferon nebulization, Interferon-beta-1a FBS-free/HSA-free, IFN beta(24 weeks), Ribavirin plus Interferon-beta-1a, IFN beta(48 weeks).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bay86-5046-interferon-beta-1b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BAY86-5046_Interferon-beta-1b — Competitive Intelligence Brief

BAY86-5046_Interferon-beta-1b (BAY86-5046_Interferon-beta-1b) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Neurology.

phase 2 Interferon Interferon-alpha/beta receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BAY86-5046_Interferon-beta-1b (BAY86-5046_Interferon-beta-1b) — Bayer. Interferon-beta-1b binds to the interferon-alpha/beta receptor, activating a signaling cascade that modulates immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BAY86-5046_Interferon-beta-1b TARGET	BAY86-5046_Interferon-beta-1b	Bayer	phase 2	Interferon	Interferon-alpha/beta receptor
Interferon Beta 1	Interferon Beta 1	University of Turin, Italy	marketed	Type I interferon	Interferon-alpha/beta receptor (IFNAR)
Ganovo+ritonavir+/-Interferon nebulization	Ganovo+ritonavir+/-Interferon nebulization	The Ninth Hospital of Nanchang	marketed	Antiviral combination therapy	Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
Interferon-beta-1a FBS-free/HSA-free	Interferon-beta-1a FBS-free/HSA-free	EMD Serono	phase 3	Interferon	Interferon-alpha/beta receptor (IFNAR)
IFN beta(24 weeks)	IFN beta(24 weeks)	Tanabe Pharma Corporation	phase 3	Interferon	Interferon-alpha/beta receptor (IFNAR)
Ribavirin plus Interferon-beta-1a	Ribavirin plus Interferon-beta-1a	EMD Serono	phase 3	Antiviral combination (nucleoside analog + cytokine)	Viral RNA polymerase (ribavirin); Interferon-alpha/beta receptor (interferon-beta-1a)
IFN beta(48 weeks)	IFN beta(48 weeks)	Tanabe Pharma Corporation	phase 3	Interferon	Interferon-alpha/beta receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAY86-5046_Interferon-beta-1b — Competitive Intelligence Brief. https://druglandscape.com/ci/bay86-5046-interferon-beta-1b. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab